Cargando…
Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system. A humanised anti-C5 monoclonal antibody (eculizumab) is available for the treatment of aHUS. We present the first description of atypical HUS in a child with a coexistent diagnosis of a POL-III leukodystro...
Autores principales: | Teoh, Chia Wei, Gorman, Kathleen Mary, Lynch, Bryan, Goodship, Timothy H. J., Dolan, Niamh Marie, Waldron, Mary, Riordan, Michael, Awan, Atif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818949/ https://www.ncbi.nlm.nih.gov/pubmed/29552364 http://dx.doi.org/10.1155/2018/2781789 |
Ejemplares similares
-
Genetics and complement in atypical HUS
por: Kavanagh, David, et al.
Publicado: (2010) -
Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019) -
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013) -
Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015) -
Atypical HUS relapse triggered by COVID-19
por: Ville, Simon, et al.
Publicado: (2021)